ContractSupply Agreement • February 23rd, 2023 • Dynavax Technologies Corp • Pharmaceutical preparations
Contract Type FiledFebruary 23rd, 2023 Company Industry[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
Amendment No. 4 to Supply AgreementSupply Agreement • February 23rd, 2023 • Dynavax Technologies Corp • Pharmaceutical preparations
Contract Type FiledFebruary 23rd, 2023 Company IndustryThis Amendment No. 4, effective as of September 23, 2022 (the "Effective Date") (“Amendment No. 4”) amends that certain Supply Agreement having an effective date of June 29, 2021 by and between the parties hereto (each a "Party" and collectively the "Parties")(the “Agreement”).
SUPPLY AGREEMENTSupply Agreement • February 23rd, 2023 • Dynavax Technologies Corp • Pharmaceutical preparations
Contract Type FiledFebruary 23rd, 2023 Company IndustryTHIS AGREEMENT is entered into as of April 1, 2021 (the “Effective Date”) by and between DYNAVAX TECHNOLOGIES CORPORATION, a company established pursuant to the laws of Delaware, with its registered office at 2100 Powell Street, Emeryville, California 94608, hereinafter referred to as “Buyer,” and BECTON, DICKINSON AND COMPANY, a corporation organized under the laws of New Jersey, with a place of business at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1866 hereinafter referred to as “BD.” Buyer and BD are also referred to collectively herein as the “Parties” and each a “Party.”
Amendment No. 3 to Supply Agreement DATED JUNE 29, 2021Dynavax Technologies Corp • February 23rd, 2023 • Pharmaceutical preparations
Company FiledFebruary 23rd, 2023 IndustryThis Amendment No.3, effective as of August 15, 2022 (the “Effective Date”) (“Amendment No.3”) amends that certain Supply Agreement having an effective date of June 29, 2021 by and between Zhejiang Clover Biopharmaceuticals, Inc., a company organized under the laws of the P.R. China (“Zhejiang Clover”), Clover Biopharmaceuticals (Hong Kong) Co., Limited, a company organized under the laws of Hong Kong (“Clover HK” and collectively with Zhejiang Clover, “Customer”), and Dynavax Technologies Corporation, a company organized under the laws of the State of Delaware, U.S.A. (“Dynavax”), the parties hereto (each a “Party” and collectively the “Parties”)(the “Supply Agreement”).